We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
KDK College of Pharmacy and Research Institute, Nandanvan, Nagpur
White patches emerge as a result of melanin loss in vitiligo, a chronic skin disorder. This happens when melanocytes—the cells that make pigment—are harmed or killed. Vitiligo is frequently linked to autoimmune mechanisms, in which the body's immune system attacks its own cells, even though the exact reason is yet unknown. Its onset is also believed to be significantly influenced by oxidative stress, environmental variables, and genetics. People of any age or background might be affected by the disorder, which can progress slowly or quickly. Based on the distribution of depigmented areas, it can be roughly classified into segmental and non-segmental forms. Although vitiligo is not contagious and does not directly endanger physical health.
The loss of functional melanocytes is an outcome of vitiligo, an acquired pigmentary condition that is often associated with other autoimmune diseases. It is typically asymptomatic. When the illness first appears, white spots of various sizes manifest on various body areas. Of all skin types, Approximately 1% of people worldwide suffer with vitiligo, typically before the age of 20.Its psychological effects on quality of life can be catastrophic because, particularly in people with dark or tan skin, body image dissatisfaction can stifle self-esteem and lead to depression.[1] The Vitiligo's pathophysiology is a fascinating condition whose origin has been the subject about much discussion. This pathophysiology of vitiligo is complicated and involves a number of interrelated factors, and its precise cause is yet unknown.[2] Vitiligo is brought on by the epidermis losing its operations melanocytes., an acquired pigmentation condition characterized by depigmented patches. Regardless of gender or colour, 0.1–2% of persons globally suffer with this illness, and is cosmetically deforming, particularly in dark-skinned people. It also increases the sensitivity of the lesional skin to sunburns. [3]
The histologic image displays an inconsistent lympho-mononuclear infiltration in the advancing vitiligo margins and a decrease in melanin and melanocytes in the white areas. The majority of the diagnostic criteria are clinical in nature and are founded on the observation of acquired, clearly defined white lesions on the skin that tend to develop centrifugally without any accompanying inflammation. Two clinical kinds of vitiligo are distinguished by a recent classification: segmental (type B) and nonsegmental (type A).[4] Therefore, in totally vitiliginous skin, Melanocytes are not visible in certain antibody for the melanocytic lineage. Electron microscopy, which is unable to detect melanocytic cells in vitiligo achromic patches, supports these histologic findings.[5]
Figure 1: Morphological Patterns of Vitiligo
Additionally, vitiligo sufferers' pigmented skin can be used to produce cultured melanocytes. An autoimmune condition that affects more than just the skin may be linked to vitiligo. The function of altered humoral immunity, cellular immunity, and autoimmunity is supported by numerous observations.[6] and the role of cytokines in vitiligo development. As the condition progresses, Immune response to melanocytes mediated by T cells is linked to the depigmentation process. Additionally, a lot of patients say that emotional stress, such as childbirth or the death of a first-degree relative, is a trigger.[7] Because of Koebner's phenomena, which states that regional skin tragedy can result in depigmented patches, New lesions may result from mechanical harm after burns and wounds. This effect is seen in most vitiligo sufferers. People of Vitiligo affects people of all ages and genders equally. an acquired, idiopathic, and widespread depigmentation condition. Over time, patients typically experience spotty and progressive skin color loss. There is ongoing discussion on the disease's cause [8].
Many sufferers are stigmatised, unwelcome focus, adverse remarks, bullying, or rejection, even though there are rarely any additional physical symptoms. It is frequently stated that the prevalence of vitiligo, particularly in India, ranges between 0.09 to 8%. [9] Patches of depigmentation are the hallmark of vitiligo, an acquired pigmentation condition. of the loss of functioning melanocytes in the epidermis. This disorder, which is particularly disfiguring to people with dark complexion, increases the skin's susceptibility to sunburns It impacts 0.1–2% of people worldwide, regardless of gender or color.[10]
The histologic image displays a decrease of melanocytes. Additionally, there is melanin in the white areas and an irregular lympho-mononuclear infiltration in the vitiligo's advancing edges.[11] The majority of the The diagnostic standards are clinical, founded on the observation of developed, distinct white skin blemishes that are nonsegmental (type A) and tend (type B) without any accompanying inflammation. Type B has greater prevalent and is distributed in a dermatological manner; it typically shows a consistent course following a quick beginning and evolution. Type A is more prevalent, may evolve over the course of a lifetime, and is often linked to autoimmune conditions like Addison's illness, pernicious anaemia, juvenile diabetes mellitus, thyroid issues, and Sutton nevus. According to Norland, another clinical classification is based on the distribution and extent of the lesion.[12]
Acne and the formation of white macules associated with melanocyte death or selective damage are the hallmarks of vitiligo, an acquired idiopathic dermatological condition. Vitiligo affects about 0.5–1% of the population.[13] India has the greatest reported prevalence (up to 8.8%), followed by Japan (1.68%2) and Mexico (2.6–4%). This face, neck, and arms are among the exposed body parts that typically experience depigmentation. Patients with vitiligo frequently experience a significant psychological load as a result of the severe symptoms. While both sexes are equally affected by this condition, women are more prone to seek treatment and to openly discuss vitiligo for cosmetic reasons.[14] According to estimates, Additionally, 20% of vitiligo patients have family members who has been diagnosed with the condition. Vitiligo frequently manifests as a clear familial clustering.4 Compared to people without a family history of the illness, Both an earlier age of onset and a longer duration are common in people with a positive family history. The ethology of vitiligo has not yet been completely understood and has been found to be caused by a variety of variables. Lerner studied 600 cases of vitiligo in the 1950s. Submit your work | www.dovepress.com Dove Press International Journal of Nanomedicine 2020:15 3267–3279 3267 ©2020 Sunetal. Dove Medical Press Limited is the publisher and license holder of this work. As long as the work is correctly credited, non-commercial usage are allowed without additional permission from Dove Medical Press Limited. The majority of patients with segmental vitiligo experienced emotional abnormalities or hyperhidrosis, according to Sun et al. Dove press sufferers, which even led to the development of the neurological theory.[15]
Tension, autoimmune disorders, Autoinflammation and melanocyte ternary have been found to be significant contributors to vitiligo as research has progressed. Among all the theories, oxidative stress12, autoimmune disease or autoinflammation8–11, and their interactions have been recognized as some of the most significant factors causing the illness.[16] Antigen-presenting cells in the illness present melanocyte antigens to T lymphocytes, which then kill the melanocytes. Patients with vitiligo have been shown to have overactive Inflammatory dendritic cells and endogenous killer cells. 9,10 An autoimmune response also causes innate cells to release a variety of cytokines, such as INF-γ,14–16 CXCL10,14,17,18 TNF-α, IL-6, and IL-1719–22. Another important risk factor for vitiligo is oxidative stress, independent of the autoinflammation explanation. Melanocytes produce poisonous melanin, which triggers the signalling route for cell stress in these cells. Furthermore, the mitochondria's vigorous energy metabolism causes reactive oxygen species (ROS) to accumulate excessively. Vitiligo also develops as a result of this.[17]
In short, chemicals linked to epidermal damage are discharged into the body, and levels of oxidative stress rise when small lesions caused by physical damage, a viral infection, or a sunburn. Molecular and oxidative stress products are released and activated. cause melanocytes to lose their adhesion and activate inflammasomes. Immune-based melanocyte destruction results from a sequence of immunoreactions that include the accumulation of certain cytotoxic T cells on the skin, the downregulation of regulatory T cell activity, the production of inflammatory cytokines and autoantibodies.[18] Similarly, oxidative stress plays a role in the development of depigmentation, and subsequent unwanted autoimmune reactions cause vitiligo.[19]
Figure 2: Demographic Age Distribution in Vitiligo Cases
HISTORY OF VITILIGO DISEASE
Background: In dermatology, Koebner's phenomenon (KP) is a well-known phenomena. The reaction bears the name of Heinrich Koebner, a German dermatologist who lived from 1838 to 1904. Koebner noted that his psoriasis patients developed fresh wounds at the locations of harm to the skin (Ko, 1877). Many papers detailing this phenomena in a variety of dermatological illnesses following various environmental triggers have been published throughout the years. "The Koebner experiment" refers to the experimental induction of this response (Miller, 1982a). Numerous attempts have been made since Koebner's discovery to shed light on the pathophysiology and this reaction's clinical relevance. The phenomenon of Koebner (KP), additionally known as "isomorphic response," is described as "the development of lesions at sites of specifically traumatized uninvolved skin of patients with cutaneous diseases." Finding the genes that cause vitiligo susceptibility To find genes that may mediate vitiligo susceptibility, three quite distinct methods have been employed. Genes that exhibit differential overexpression or underexpression in vitiligo patients' cells or tissue compared to controls, or between disease tissue and patient normal tissue, have been identified by gene expression analysis. These investigations can produce lists of potential genes, but is unable to differentiate between genes with main effects and the several other genes whose expression might be secondarily dysregulated or that exhibit "differential" phrasing as a result of individual variation brought on by humans' outbred genetic background. Based on an a priori biological premise, certain potential Genetic association studies have been used to evaluate genes that may contribute to vitiligo susceptibility. It has been suggested that vitiligo is polygenic. Numerous genetic loci are shared by various autoimmune illnesses, and over 50 loci have been linked to vitiligo. Andersen and Spritz (2017) A meta-analysis revealed a strong correlation between vitiligo and HLA-A2, which was followed by correlations with additional significant histocompatibility complex class I and II genes. Additional genetic associations that suggest the importance of melanocyte stress, apoptosis, and innate/adaptive immunity in the pathophysiology of vitiligo include CTLA4, PTPN22, NLRP1, GZMB, IL2RA, FOXP1, FOXD3, XPB1, MC1R, and TYR (Liu et al., 2007; Spritz & Andersen, 2017). Andersen and Spritz (2017).
OBJECTIVE:
LITERATURE REVIEW
Vitiligo is an acquired depigmentary disorder characterized by the progressive loss of melanocytes, resulting in the appearance of white patches on the skin and sometimes hair and mucous membranes. The global prevalence of vitiligo varies widely, ranging from approximately 0.1% to 8%, depending on the population studied. Although once considered merely a cosmetic condition, recent evidence highlights its significant psychological and quality-of-life (QoL) burden on affected individuals.
The exact etiology of vitiligo remains unclear; however, it is widely accepted as a multifactorial disease involving genetic, autoimmune, and environmental factors. Autoimmunity is considered the primary mechanism, where the immune system targets and destroys melanocytes. Recent studies have also emphasized the role of oxidative stress, genetic susceptibility loci, and immune mediators such as cytokines in disease progression. Additionally, resident memory T cells (TRM) have been identified as key contributors to disease persistence and recurrence, suggesting that vitiligo may function as a “memory skin disorder.”
Several theories, including autoimmune, biochemical, and neurological hypotheses, have been proposed to explain melanocyte destruction. Increasing evidence supports a combined effect of oxidative stress and immune dysregulation. Genetic studies further indicate that both common and rare genetic variations contribute significantly to disease susceptibility, while environmental triggers account for a smaller proportion of risk.
Clinically, vitiligo presents as depigmented macules and can be classified into segmental and non-segmental types, with disease activity categorized as stable or progressive. Despite advances in understanding, there is no universally accepted method for assessing disease severity. Tools such as the Vitiligo Area Scoring Index (VASI) and Vitiligo European Task Force (VETF) have been developed to standardize evaluation, often incorporating clinical observation, imaging, and colorimetric techniques.
Management strategies include pharmacological treatments, phototherapy, and surgical interventions; however, none provide a definitive cure. Treatment outcomes depend on multiple factors, including disease type, lesion stability, and patient-specific characteristics. Emerging approaches, such as nanotechnology-based therapies, aim to improve drug delivery and therapeutic efficacy.
Overall, vitiligo is a complex disorder with significant clinical and psychosocial implications, necessitating continued research into its pathogenesis and development of more effective treatment strategies.
THE VITILIGO DISEASE SYMPTOMS
The depigmentation of skin patches is the most significant known symptom of vitiligo. The patches are little at first, but they will eventually get bigger. The cheeks, hands, and wrists are where the skin lesions are most frequently seen. Patients with this illness frequently experience depression as well.
Signs of vitiligo include:
• A patchy loss of skin tone that typically starts on the hands, face, and regions surrounding bodily openings and genitalia.
• Early greying or beard bleaching, eyelashes, eyebrows or hair on the scalp
• The mucous membranes that line The colour of the inside of the nose and lips has faded.
• Although Vitiligo usually appears before the age of thirty, though it can start at any age.
The type of vitiligo will determine you have, it could impact:
• Nearly all skin surfaces. This kind, known as worldwide vitiligo, discolors almost every surface of the skin.
• A range of body parts. In this most common type, called generalised vitiligo, the discoloured patches often appear symmetrically on corresponding body parts.
• Only one side or section of the body. This type, called segmental vitiligo, typically begins earlier in life, gets worse for a year or two, and then fades away.
• One or a few body components. This type of vitiligo is known as localised (focal).
• The face and hands. This type, called acrofacial vitiligo, affects the skin around body openings such as the nose, ears, and eyes as well as the hands and face.
The course of this illness is hard to forecast. Without therapy, Occasionally, the patches might stop showing. Most of the skin eventually becomes affected by pigment loss as it advances. The skin occasionally regains its color.[20]
Figure 3: Understanding Vitiligo
CAUSES OF VITILIGO DISEASE
Figure 4: Possible Causes Of vitiligo
The absence of melanin, a pigment, in the skin is the cause of vitiligo.
Your skin or hair may have white patches. caused by other factors. Melanin, Melanocytes generate the pigment that gives your skin, hair, and eyes their colour. which die or cease to do so as vitiligo develops. The affected skin areas lighten or turn whiteIt's unclear exactly why these pigment cells fail or die.
It could be connected to:
• An immune system disorder (autoimmune disease)
• Heredity, or family history
• A trigger event, such stress, a severe sunburn, or skin damage, like coming into contact with a chemical
Figure 5: Structure of human skin
Melanin, a naturally occurring pigment in the layers of skin, is what provides your skin its hue. Melanin is synthesized in cells.
VITILIGO DISEASE PATHOGENESIS
Three ideas exist about the pathophysiology of vitiligo, despite the fact that its precise cause is unknown: autoimmune, neurological, and biochemical/cytotoxic. The biochemical/cytotoxic theory highlights that vitiligo develops when melanocytes are killed by cytotoxic precursors to melanin synthesis; the neural theory is based on the development of nerve injury with affected sites that results in segmental vitiligo with neurons that interact with melanocytes and release melanocyte toxic substrates; and the autoimmune hypothesis is based on genetic data that are more closely linked to autoimmune disease.[21]
The cause of In vitiligo, a fascinating condition that has been the subject of much discussion. The pathophysiology of vitiligo is complicated and includes the interaction of numerous factors, and the precise cause of the condition is yet unknown.[22] A multifactorial genetic component predisposes some people to vitiligo, and about one-third of those who have the condition have a family history. Additionally, there is compelling genetic evidence that vitiligo and other autoimmune illnesses are related. [23] Autoimmune Diseases Segmental vitiligo follows the same path as dermatome, and malfunctions in the sympathetic nervous system can lower melanin production and result in depigmentation. according to the neural theory. According to the intrinsic view, vitiligo melanocytes die as a result of faults. These include diminished adhesive qualities, morphologic abnormalities, and insufficient melanocyte development factors.[24] Melanocyte destruction has also been shown to be significantly influenced by increased oxidative stress. [25]
widely accepted explanation of autoimmune-mediated melanocyte death appears to be the most prominent theory regarding the pathophysiology of vitiligo. Cytokines, humoral antibody-mediated immunity, and cellular immunity can all contribute to the immunological response. In vitiligo, the effect of antibodies against a number of antigens linked to melanocytes was confirmed. These antibodies mostly recognise tyrosinase, but they have also been found to recognise pigment cell surface antigens, tyrosine hydroxylase, and antithyroid antigens.[26]
Inflammatory infiltrates in perilesional vitiligo skin are indicative of vitiligo's cell-mediated defence. Vitiligo-affected skin has a lower ratio of CD4+ to CD8+ lymphocytes than healthy skin, and vitiligo patients' blood and perilesional skin both contain CD8 T cells that are directed against melanocytic antigens. [27] This demonstrates The elimination of melanocytes by cytotoxic T cells is one mechanism responsible for depigmentation in vitiligo. Cytokines also seem to play an important role in the pathophysiology of vitiligo. Tumor necrosis alpha (TNF-????) and interferon-gamma (IFN-????) expression are elevated, indicating that Vitiligo is caused by a T helper cell-1 (Th1) response.[28]
TREATMENT OF VITILIGO DISEASE
There are no therapies that guarantee a full recovery from vitiligo. Controlling melanocytes being destroyed by the immune system or promoting their proliferation on afflicted areas is the primary objective of current therapy. Encomia can be treated with medication, physical therapy, surgery, or a mix of these methods. Mela genuine (human placental exact) and vitamin derivative (NB-UVB), excimer laser, topical calcineurin inhibitors such tacrolimus and pimecrolimus, pseudo catalase, and systemic and topical corticosteroid therapy are the pharmacological treatment options. In addition to topical therapy and transplantation procedures, these treatments are complimentary.[29] Individuals with stable vitiligo, meaning that neither the quantity nor the shape of lesions have changed who have not responded well to conventional therapies may be candidates for surgery. applying a donor's pigmented skin graft to the patient's affected areas is the most common method, while there are other approaches. Suction blister grafts, punch grafts, mini grafts, and split thickness skin grafts are examples of surgical procedures. [30]
Another surgical procedure is melanocyte and keratinocyte transplantation, which involves transferring cell suspension onto a recipient from a donor's pigmented skin who has already been prepared, typically through dermabrasion. It is possible to employ both cultivated and uncultured cells. According to data previously gathered by our research, non-cultured melanocytes-keratinocytes cellular grafting produces notable pigmentation results in individuals with stable types of vitiligo.[31] Because vitiligo can be caused by a variety of unidentified reasons, each patient's outcome is unique and rarely satisfactory. In order to forecast and provide the best course of treatment for each patient, it is essential to understand the immunological factors linked to vitiligo etiology.Numerous investigations have demonstrated T cell involvement in vitiligo pathogenesis, and vitiligo skin regularly exhibits a CD8 T-cell infiltration. Additionally, vitiligo lesions frequently return on comparable anomic areas following regimentation, indicating TRM involvement. In Patients with vitiligo who have stable or active illness, we have discovered subgroups of CD69+ CD103+ and CD69+ CD103-TRM that accumulate in both the dermis and the epidermis of skin that is perilesional, with CD103+ TRM being more prevalent within the skin. Melanocyte-specific TRM is characterised by the expression of CXCR3 and increased levels of the pro-inflammatory cytokines TNFα and interferon IFNY. TRM expressing CD49a was also observed in the dermis and epidermis of vitiligo lesional skin. They were distinguished by the production of IFNY, perforin, and granzyme B [11], particularly when TRM cells were cultured in the presence of IL-15, a cytokine that has been demonstrated to be involved in TRM differentiation and maintenanceVitiligo linked to melanoma promotes TRM, which can provide in vivo anti-tumor immunity. which is consistent with TRM's role in vitiligo. The loss of lipocytes seen in vitiligo will be further influenced by soluble substances generated by TRM. In fact, melanocyte function has been demonstrated to be inhibited by TNFα or IFNY, among other amatory cytokines.[4] Vitiligo skin has also been shown to have dysfunctional regulatory T cells (Tregs), and replenishing these cells may be useful to prevent depigmentation. Remarkably, it has been demonstrated that skin-resident regulatory T lymphocytes are essential for the regeneration of hair follicle stem cells. [32]
RISK FACTORS OF VITILIGO DISEASE
Risk Factors in Lifestyle
It is impossible to predict a person's risk of developing vitiligo. However, a number of risk factors have been found by specialists that are believed to raise the likelihood, especially If the person is genetically predisposed to the disorder. Trauma or Defects to the Skin According to research, areas that have experienced Frequent sun exposure and severe sunburns, usually on the hands, neck, and face, may increase the risk of developing vitiligo.
Vitiligo may also be more prone to develop in areas of the skin that have experienced trauma, such as a deep cut or frequent rubbing, friction, scratching, or pressure.
Anxiety
Research has demonstrated that both the onset and advancement of vitiligo can be triggered by stressful events or long-term emotional and physical stress, especially in patients who are genetically susceptible.
The hormonal alterations brought on by extreme tension are assumed to be the cause of the skin changes, at least in part. Additionally, there is evidence linking autoimmune diseases to trauma and other life stressors.
Chemical Exposure
Another environmental risk factor for vitiligo development may be contact with or exposure to specific substances. According to some researchers, the chemicals cause autoimmune inflammation by speeding up stress pathways that melanocytes already have.
Furthermore, genetic factors may raise melanocyte cellular stress or lower the immune system's sensitivity for stress.
Monobenzone, which is included in several goods including rubber, leather, and cosmetic colors, is one of the substances that has been researched. According to research, monobenzone can cause vitiligo sufferers' skin depigmentation to worsen.
Phenols are another class of chemicals that may contribute to vitiligo since they are believed to interfere with melanocyte function. These substances are frequently found in goods including paints, adhesives, pesticides, disinfectants, and more.
CONCLUSION
Based on They findings, I'd want to draw the conclusion that vitiligo is an acquired, largely asymptomatic pigmentary condition that results in the death of functional melanocytes and is often associated with other autoimmune diseases. White patches of varying sizes at the beginning of the illness appear on various body areas.( Melanocytes are the cells that produce the pigment that gives skin and hair its colour ) Approximately 1% of people worldwide, regardless of skin type, suffer from this condition, typically prior to turning 20. In essence, That's a skin condition that produces white patches.It is brought on by a lack of the skin's melanin pigment. though the precise etiology is unknown and may involve a mix of environmental and hereditary factors. pathogenesis, encompassing three theories: autoimmune, neurological, and biochemical/cytotoxic. Although the precise etiology of vitiligo is still unknown, but there are a number of theories regarding its aetiology. Symptoms include fast pigment loss, sensitivity to sunlight, and skin and muscle membrane colour loss. AGE: It usually appears before the age of thirty, but it can start at any age. Blood testing, skin biopsy, and Wood's lamp examination may be used to make the diagnosis. Vitiligo cannot be fully cured. Controlling The main goal of current therapy is to either promote the development of melanocytes in affected areas or destroy them due to autoimmune reactions.
REFERENCES
Aditi Chambhare, Rahul Lichade, Prajakta Vaidya, Kartik Mirche, Chetna Hiwase, Kamlesh Wadher, A Comprehensive Review on Vitiligo: History, Symptoms, Causes, Pathogenesis, Risk Factors, and Treatment, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 3913-3924, https://doi.org/10.5281/zenodo.19707051
10.5281/zenodo.19707051